Kings Research today announced the release of its latest market intelligence study, “Global Fecal Calprotectin Test Market: Size, Share, Trends & Forecast 2025–2032.” The report provides an in-depth analysis of market drivers, emerging trends, regulatory developments, and the competitive landscape shaping the gastrointestinal diagnostics sector.
According to Kings Research, the global fecal calprotectin test market was valued at USD 3,026.2 million in 2025, and is projected to reach USD 4,687.1 million by 2032, growing at a CAGR of 6.45% during 2025–2032. Market expansion is propelled by the increasing prevalence of inflammatory bowel diseases (IBD), demand for early and accurate gastrointestinal (GI) diagnostics, and advancements in assay sensitivity and automation.
Fecal calprotectin tests measure levels of calprotectin (a biomarker of intestinal inflammation) in stool samples to differentiate between inflammatory and non-inflammatory GI disorders. The market includes enzyme-linked immunosorbent assays (ELISA) and lateral flow immunoassays, both widely adopted in clinical and laboratory settings for their accuracy and ease of use. Key applications range from IBD diagnosis to early GI screening and disease monitoring.
Kings Research identifies the following growth accelerators:
- Rising Prevalence of IBD
The Centers for Disease Control and Prevention (CDC) reported that between 2.4 and 3.1 million U.S. adults were living with IBD in 2024, underscoring growing global demand for reliable, non-invasive diagnostics. (Source: www.cdc.gov). Fecal calprotectin testing provides a sensitive biomarker for early detection and ongoing monitoring of Crohn’s disease and ulcerative colitis, reducing reliance on colonoscopies.
- Shift Toward Point-of-Care Assays
Rapid, on-site testing shortens turnaround times and improves patient management.
- Technological Advancements & Automation
High-sensitivity ELISA platforms and automated analyzers such as Sysmex SENTiFIT 270 and 800 streamline laboratory workflows, increase throughput, and improve diagnostic accuracy. January 2025: Sysmex America signed an agreement with Sentinel Diagnostics to distribute these automated analyzers in Canada to support colorectal cancer and calprotectin testing. (Source: www.sysmex.com)
- Expanding Access in Emerging Markets
Healthcare infrastructure upgrades in Asia-Pacific, Latin America, and the Middle East are facilitating broader test adoption.
For hospitals, diagnostic labs, and clinicians, fecal calprotectin testing offers:
- Non-Invasive Precision: Accurate inflammation detection without invasive procedures.
- Operational Efficiency: Automation-compatible platforms reduce turnaround times and labor requirements.
- Cost Savings: Early detection and disease monitoring help lower long-term treatment costs by preventing complications.
Regional Outlook
- North America: Largest market with 36.73% share (USD 1,052.4 million in 2024), driven by high IBD prevalence, advanced healthcare infrastructure, and strong reimbursement frameworks.
- Asia-Pacific: Expected to experience the fastest growth (7.45% CAGR) through 2032, fueled by expanding laboratory networks and increasing awareness of non-invasive GI diagnostics.
- Europe, Latin America, Middle East & Africa: Experiencing steady adoption supported by regulatory harmonization and rising investments in precision medicine.
Competitive Landscape
The market is moderately fragmented, with companies focusing on high-sensitivity assays, point-of-care innovations, and strategic partnerships. Key players include ALPCO, ORGENTEC Diagnostika, EagleBio, F. Hoffmann-La Roche Ltd, Alpha Laboratories, DiaSorin S.p.A., Immundiagnostik AG, BÜHLMANN, and Epitope Diagnostics, Inc.
The full Kings Research report provides detailed segmentation by test type, application, end user, and region, along with competitive benchmarking and long-term market forecasts. To request a sample or access the complete report, please visit https://www.kingsresearch.com/fecal-calprotectin-test-market-368.
About Kings Research
Kings Research is a global provider of syndicated research reports and consulting services, helping organizations navigate emerging markets, assess opportunities, and make informed business decisions.
All market data are sourced from Kings Research proprietary analysis, validated against credible public sources such as the U.S. Centers for Disease Control and Prevention (www.cdc.gov) and the U.S. Food and Drug Administration (www.fda.gov).